New trial data on CagriSema 23% weight loss at 84 weeks in the RE DEFINE 4 trial. CagriSema pairs semaglutide with cagrilintide, an amylin analogue. Amylin is a pancreatic hormone that slows EASD e Learning Provided by leading diabetes academics PDF] Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial. Semantic Scholar Three new #obesity drugshigh dose semaglutide, semaglutide plus cagrilintide, and oral orforglipronmay soon be approved in the US. JAMA Medical News Director Jennifer Abbasi and Lead Senior Staff Writer Rita Rubin examine how Supplementary appendix